Details of the Drug

General Information of Drug (ID: DMHVEGJ)

Drug Name

CC-930

Synonyms

TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358

Indication

Disease Entry	ICD 11	Status	REF
Discoid lupus erythematosus	EB51.0	Phase 2	[1]
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

448.4

Logarithm of the Partition Coefficient (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C21H23F3N6O2
IUPAC Name: 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
Canonical SMILES: C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O
InChI: InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
InChIKey: IBGLGMOPHJQDJB-MOKVOYLWSA-N

Cross-matching ID

PubChem CID: 11597537
CAS Number: 899805-25-5
UNII: M5O06306UO
DrugBank ID: DB11798
TTD ID: D0X4MN

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Jun N terminal kinase (JNK)	TTR2TXZ	MK08_HUMAN ; MK09_HUMAN ; MK10_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
2	In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.